​INNODIA (an innovative approach towards understanding and arresting type 1 diabetes)is an international consortium consisting of academic institutions including SDCC, clinics, patient organizations, partners and enterprises.

The mission is to understand at the cellular and molecular levels distinctive paths of ontogeny and progression in type 1 diabetes (T1D), thus impacting on the future management of patients and at risk individuals. 

Despite significant progress in preclinical type 1 diabetes (T1D) research, it has not been possible to translate the findings from in vitro models and animal studies into novel and effective clinical interventions. INNODIA will establish a comprehensive and interdisciplinary network of clinical and basic scientists, who are leading experts in the field of T1D research in Europe, with complementary expertise from the areas of immunology, beta‐cell biology and biomarker research.
Learn more on the innodia website


The overall objective of INNODIA is to advance in a decisive way how we predict, evaluate and prevent the onset and progression of T1D, by creating novel tools, including biomarkers, disease models and clinical trial paradigms.


More than 30 academic and EFPIA Partners.
Key collaborators are:
Søren Brunak, University of Copenhagen, Denmark
Decio L. Eizirik, University of Brussels, Belgium
Jesper Johannesen, Copenhagen University Hospital Herlev, Denmark


IMI2, EU, JDRF, Helmsley Foundation

Responsible editor